The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

NovoFine Autocover 30G disposable safety needles were dispensed for patients enrolled in the pen group. If insulin glargine was prescribed, a vial was dispensed regardless of the treatment group ...

Soliqua 100/33 (insulin glargine/lixisenatide) is a prescription drug that’s used to treat type 2 diabetes. Soliqua 100/33 comes as a prefilled single-use pen for injecting the drug under your skin.

Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...

Lilly/Boehringer Ingelheim's insulin glargine product will be available in a pre-filled pen and cartridges for a reusable pen. The marketing authorisation for the Alliance's insulin glargine ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

Soliqua is a once-daily injectable combination drug containing insulin, glargine 100 units/ml ... available at a therapy cost of Rs 1,850 per pen. "The inclusion of Soliqua to our comprehensive ...